IPO - iSpecimen Inc.

Form Type: S-1/A

Filing Date: 2025-05-23

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025047292

Filing Summary: This document is an amendment to the Form S-1 registration statement under the Securities Act of 1933 for iSpecimen Inc., filed to register its common stock offerings including up to ___________ shares of common stock and Pre-Funded Warrants. iSpecimen aims to connect life science researchers with biospecimens through its proprietary marketplace technology. The document outlines the company's mission, market opportunities, operational efficiencies, and technological advancements designed to enhance user experience in biospecimen procurement. It includes plans for future developments in their marketplace, enhancing customer and supplier engagement through improved operational efficiencies. The underwriters for this offering include WestPark Capital, Inc. The document serves as a preliminary prospectus subject to completion and reflects the company’s commitment to submitting this registration statement for effective date.

Form Type: S-1

Filing Date: 2025-05-02

Corporate Action: Ipo

Type: New

Accession Number: 000121390025039321

Filing Summary: iSpecimen Inc. filed a registration statement under the Securities Act of 1933 on May 2, 2025, aiming to sell up to 2,362,205 shares of its common stock and corresponding Pre-Funded Warrants to facilitate a public offering. The shares are expected to be priced at approximately $1.27 each, which reflects the closing price on April 30, 2025, for its common stock listed on Nasdaq under the symbol 'ISPC'. This registration statement marks a significant step for the company in its mission to improve biospecimen procurement for research purposes. The offering is underwritten on a firm commitment basis by WestPark Capital, Inc. Investors will have the option to purchase Pre-Funded Warrants to avoid exceeding a 4.99% ownership threshold. Notably, the Pre-Funded Warrants are designed to enhance liquidity for major stakeholders while allowing the company to manage its equity effectively. The company positions itself as an emerging growth company and smaller reporting company, which allows it certain regulatory benefits in the IPO process. The funds raised will support further development and enhancements of the iSpecimen Marketplace technology that connects life science researchers with necessary specimens, thereby facilitating faster and more efficient medical research.